丹参川芎嗪对慢性阻塞性肺疾病合并呼吸衰竭患者肺功能、炎性反应因子的变化(1)
摘要 目的：探討丹参川芎嗪治疗慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Diseases，COPD)合并呼吸衰竭的临床疗效及对患者肺功能、血气指标、炎性反应因子的影响。方法：选取COPD合并呼吸衰竭患者98例，并随机分为治疗组和对照组，各49例。对照组采用常规西医治疗，治疗组在对照组的基础上加用丹参川芎嗪治疗，2组均连续治疗14 d。评价2组患者临床疗效，检测并比较2组患者肺功能指标、血气指标、炎性反应因子水平的变化。结果：治疗组总有效率为97.96%，显著高于对照组的83.67%(P<0.05)；治疗后2组FEV1、FVC、FEV1/FVC等肺功能指标，PaO2和SaO2水平均较治疗前显著升高(P<0.01)，且治疗组显著高于对照组(P<0.05或P<0.01)，2组PaCO2水平较治疗前显著下降，且治疗组显著低于对照组(P<0.01)；治疗后2组血清IL-6、IL-8、CRP、TNF-α水平均较治疗前显著降低(P<0.01)，且治疗组显著低于对照组(P<0.01)。结论：丹参川芎嗪治疗COPD合并呼吸衰竭患者，可有效降低机体炎性反应因子水平，改善患者血气指标，进而促进其肺功能的恢复，效果确切。
, 百拇医药
关键词 慢性阻塞性肺疾病；呼吸衰竭；丹参川芎嗪；肺功能；血气；炎性反应因子
Abstract Objective：To investigate the clinical effect of salvia miltiorrhiza ligustrazine on chronic obstructive pulmonary disease (COPD) complicated with respiratory failure and its effect on pulmonary function， blood gas and inflammatory factors. Methods：Ninety-eight patients with COPD complicated with respiratory failure were selected and randomly divided into a treatment group and a control group， each 49 cases. The control group was treated with conventional western medicine， while the treatment group was treated with salvia miltiorrhiza ligustrazine on the basis of the control group， all treated for 14 d. The clinical efficacy of the 2 groups were evaluated， and the changes of pulmonary function， blood gas and inflammatory factors were detected and compared between the 2 groups. Results：The total effective rate of the treatment group was 97.96%， which was significantly higher than 83.67% of the control group (P<0.05)； After treatment， the FEV1， FVC， FEV1/FVC of 2 groups， PaO2 and SaO2 levels of 2 groups were significantly higher than before treatment (P<0.01)， and the treatment group was significantly higher than that of the control group (P<0.05 or P<0.01). The level of PaCO2 in 2 groups was significantly lower than that before treatment， and the treatment group was significantly lower than the control group (P<0.01)； after treatment， the levels of serum IL-6， IL-8， CRP and TNF-α in 2 groups were significantly lower than those before treatment (P<0.01)， and the treatment group was significantly lower than those in the control group (P<0.01). Conclusion：Salvia miltiorrhiza ligustrazine can effectively reduce the levels of inflammatory factors in patients with COPD complicated with respiratory failure， improve the blood gas index， and then promote the recovery of lung function with precise clinic effect.
Key Words Chronic obstructive pulmonary disease； Respiratory failure； Salvia miltiorrhiza ligustrazine； Pulmonary function； Blood gas； Inflammatory factor, 百拇医药(贾铷 陈运转 祝伟)
, 百拇医药
关键词 慢性阻塞性肺疾病；呼吸衰竭；丹参川芎嗪；肺功能；血气；炎性反应因子
Abstract Objective：To investigate the clinical effect of salvia miltiorrhiza ligustrazine on chronic obstructive pulmonary disease (COPD) complicated with respiratory failure and its effect on pulmonary function， blood gas and inflammatory factors. Methods：Ninety-eight patients with COPD complicated with respiratory failure were selected and randomly divided into a treatment group and a control group， each 49 cases. The control group was treated with conventional western medicine， while the treatment group was treated with salvia miltiorrhiza ligustrazine on the basis of the control group， all treated for 14 d. The clinical efficacy of the 2 groups were evaluated， and the changes of pulmonary function， blood gas and inflammatory factors were detected and compared between the 2 groups. Results：The total effective rate of the treatment group was 97.96%， which was significantly higher than 83.67% of the control group (P<0.05)； After treatment， the FEV1， FVC， FEV1/FVC of 2 groups， PaO2 and SaO2 levels of 2 groups were significantly higher than before treatment (P<0.01)， and the treatment group was significantly higher than that of the control group (P<0.05 or P<0.01). The level of PaCO2 in 2 groups was significantly lower than that before treatment， and the treatment group was significantly lower than the control group (P<0.01)； after treatment， the levels of serum IL-6， IL-8， CRP and TNF-α in 2 groups were significantly lower than those before treatment (P<0.01)， and the treatment group was significantly lower than those in the control group (P<0.01). Conclusion：Salvia miltiorrhiza ligustrazine can effectively reduce the levels of inflammatory factors in patients with COPD complicated with respiratory failure， improve the blood gas index， and then promote the recovery of lung function with precise clinic effect.
Key Words Chronic obstructive pulmonary disease； Respiratory failure； Salvia miltiorrhiza ligustrazine； Pulmonary function； Blood gas； Inflammatory factor, 百拇医药(贾铷 陈运转 祝伟)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 其它 > 呼吸衰竭